Evaluation of in-house genotyping assay performance using dried blood spot specimens in the Global World Health Organization laboratory network.
about
Development, validation and clinical evaluation of a low cost in-house HIV-1 drug resistance genotyping assay for Indian patientsPerformance of an in-house human immunodeficiency virus type 1 genotyping system for assessment of drug resistance in CubaViral load detection using dried blood spots in a cohort of HIV-1-infected children in Uganda: correlations with clinical and immunological criteria for treatment failureField study of dried blood spot specimens for HIV-1 drug resistance genotypingPrevalence of transmitted HIV-1 antiretroviral resistance among patients initiating antiretroviral therapy in Brazil: a surveillance study using dried blood spots.Antiretroviral treatment outcome in HIV-1-infected patients routinely followed up in capital cities and remote areas of Senegal, Mali and Guinea-Conakry.The design and evaluation of a shaped filter collection device to sample and store defined volume dried blood spots from finger pricks.Comparison of HIV-1 resistance profiles in plasma RNA versus PBMC DNA in heavily treated patients in Honduras, a resource-limited countryUpdate on World Health Organization HIV drug resistance prevention and assessment strategy: 2004-2011Field evaluation of a broadly sensitive HIV-1 in-house genotyping assay for use with both plasma and dried blood spot specimens in a resource-limited country.Field evaluation of dried blood spots for routine HIV-1 viral load and drug resistance monitoring in patients receiving antiretroviral therapy in Africa and Asia.Implementing HIV-1 genotypic resistance testing in antiretroviral therapy programs in Africa: needs, opportunities, and challenges.HIV Resistance with Correlation to PMTCT Regimen in HIV-Infected Infants in Northern Tanzania.High efficacy of first-line ART in a West African cohort, assessed by dried blood spot virological and pharmacological measurements.
P2860
Q28542561-38ED4DB0-D3A0-4D64-A506-B9A5A3024F52Q28543384-61EA55DD-7127-4C53-8D2D-6044EEAFD9AFQ33900125-FA2B16D6-A47A-4BC6-A523-29A316E2E0F1Q34058841-21F9D6C4-E2D8-48B7-84BE-E71DDFDF89D4Q34232916-AA1C69CC-D597-448D-AE34-2DB352696AB7Q34745289-7E2942D2-D00A-42C5-A45F-0B3C5237D592Q35083089-2922D240-B22B-42EB-B0A2-6CBE113C2B29Q35862718-C8993765-3DA6-4FF6-BC8D-276146BC2915Q35917578-7FB9CE4C-68A7-4B1A-8EFE-DD88C3A131F3Q36558961-FD78511A-C11F-421B-813E-3650022217CCQ37546113-EF788D2B-0AE6-4418-BF53-664AFA908FF3Q37634044-30D55653-114A-4399-9A76-0980AE2AA08CQ38630228-BB9BBD4A-E293-4EA4-900E-128EE73553FEQ40606010-89EA497E-F7F1-4938-B7A1-3E4AF4A75990
P2860
Evaluation of in-house genotyping assay performance using dried blood spot specimens in the Global World Health Organization laboratory network.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Evaluation of in-house genotyp ...... ganization laboratory network.
@ast
Evaluation of in-house genotyp ...... ganization laboratory network.
@en
type
label
Evaluation of in-house genotyp ...... ganization laboratory network.
@ast
Evaluation of in-house genotyp ...... ganization laboratory network.
@en
prefLabel
Evaluation of in-house genotyp ...... ganization laboratory network.
@ast
Evaluation of in-house genotyp ...... ganization laboratory network.
@en
P2093
P2860
P356
P1476
Evaluation of in-house genotyp ...... ganization laboratory network.
@en
P2093
Carmen de Mendoza
Cheryl Jennings
James Bremer
Michael R Jordan
Neil Parkin
Rob Schuurman
Silvia Bertagnolio
WHO DBS Genotyping Working Group
P2860
P304
P356
10.1093/CID/CIR982
P407
P478
54 Suppl 4
P577
2012-05-01T00:00:00Z